



HAL
open science

Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins

Stefania Robakiewicz, Clarisse Bridot, Sonia Serna, Ana Gimeno, Begoña Echeverria, Sandra Delgado, Jerome de Ruyck, Shubham Semwal, Diego Charro, Ann Dansercoer, et al.

► **To cite this version:**

Stefania Robakiewicz, Clarisse Bridot, Sonia Serna, Ana Gimeno, Begoña Echeverria, et al.. Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins. *Glycobiology*, 2021, *Glycobiology*. hal-03283666v2

HAL Id: hal-03283666

<https://hal.univ-lille.fr/hal-03283666v2>

Submitted on 14 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins

Journal:	<i>Glycobiology</i>
Manuscript ID	GLYCO-2021-00007.R1
Manuscript Type:	Regular Manuscripts
Date Submitted by the Author:	03-Mar-2021
Complete List of Authors:	<p>Robakiewicz, Stefania; CNRS, UGSF UMR 8576; Bridot, Clarisse; CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 du CNRS Serna, Sonia; CIC biomaGUNE, Biofunctional Nanomaterials Unit Gimeno, Ana; CICBIOGUNE, Chemical Glycobiology Lab Echeverria , Begoña; CIC biomaGUNE, Glycotechnology Lab Delgado, Sandra; CICBIOGUNE, Chemical Glycobiology Lab de Ruyck, Jerome; CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 du CNRS Semwal, Shubham; CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 du CNRS Charro, Diego; CICBIOGUNE, Structure and Cell Biology of Viruses Lab Dansercoer, Ann; VIB-UGent Center for Inflammation Research, Department of Biochemistry and Microbiology Verstraete , Kenneth ; VIB-UGent Center for Inflammation Research, Department of Biochemistry and Microbiology Azkargorta, Mikel; CICBIOGUNE, Chemical Glycobiology Lab Van Noort, Kim; Wageningen Universiteit en Research, Department of Plant Sciences, Laboratory Wilbers, Ruud; Wageningen Universiteit en Research, Department of Plant Sciences, Laboratory; Savvides, Savvas; Ghent University, Biochemistry and Microbiology Abrescia, Nicola; CICBIOGUNE, Structure and Cell Biology of Viruses Lab Arda, Ana; CICBIOGUNE, Chemical Glycobiology Lab Reichardt, Niels; CIC biomaGUNE, Biofunctional Nanomaterials Unit Jimenez-Barbero, Jesus; CIC bioGUNE, Chemical Glycobiology Bouckaert, Julie; CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 du CNRS</p>
Key Words:	Mannitou, IgM, paucimannose, N-glycan, core fucose

Minimal epitope for Mannitou IgM on paucimannose-carrying glycoproteins

Stefania Robakiewicz^{1#}, Clarisse Bridot^{1#}, Sonia Serna^{2#}, Ana Gimeno³, Begoña Echeverria², Sandra Delgado³, Jérôme de Ruyck¹, Shubham Semwal¹, Diego Charro³, Ann Dansercoer⁴, Kenneth Verstraete⁴, Mikel Azkargorta³, Kim van Noort⁵, Ruud Wilbers⁵, Savvas N. Savvides⁴, Nicola G. A. Abrescia^{3,6}, Ana Arda³, Niels C. Reichardt^{2*}, Jesús Jiménez-Barbero^{3,6*} and Julie Bouckaert^{1*}

¹ *Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 du CNRS et Université de Lille, 50 Avenue Halley, 59650 Villeneuve d'Ascq, France;*

² *Glycotechnology Laboratory, Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 San Sebastian, Spain;*

³ *CIC bioGUNE, Bizkaia Science and Technology Park, 48160 Derio, Spain;*

⁴ *Unit for Structural Biology, VIB – UGent Center for Inflammation Research, Department of Biochemistry and Microbiology, Ghent University, Technologiepark 71, 9052 Ghent, Belgium;*

⁵ *Laboratory of Nematology, Plant Science Group, Wageningen University and Research, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands;*

⁶ *IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain.*

First authors who have made equal contributions

* To whom correspondence may be addressed:

Niels Reichardt nreichardt@cicbiomagune.es

Jesús Jiménez-Barbero jjbarbero@cicbiogune.es

Julie Bouckaert julie.bouckaert@univ-lille.fr

Abstract

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Paucimannosidic glycans are restricted to the core structure [Man₁₋₃GlcNAc₂Fuc₀₋₁] of *N*-glycans and are rarely found in mammalian tissues. Yet, especially [Man₂₋₃GlcNAc₂Fuc₁] have been found significantly upregulated in tumors, including in colorectal and liver cancer. Mannitou IgM is a murine monoclonal antibody that was previously shown to recognise Man₃GlcNAc₂ with an almost exclusive selectivity. Here, we have sought the definition of the minimal glycan epitope of Mannitou IgM, initiated by screening on a newly designed paucimannosidic glycan microarray. Among the best binders were Man₃GlcNAc₂ and its α 1,6 core-fucosylated variant, Man₃GlcNAc₂Fuc₁. Unexpectedly and in contrast to earlier findings, Man₅GlcNAc₂-type structures bind equally well and a large tolerance was observed for substitutions on the α 1,6 arm. It was confirmed that any substitution on the single α 1,3-linked mannose completely abolishes binding. Surface plasmon resonance for kinetic measurements of Mannitou IgM binding, either directly on the glycans or as presented on omega-1 and kappa-5 soluble egg antigens from the helminth parasite *Schistosoma mansoni*, showed submicromolar affinities. To characterize the epitope in greater and atomic detail, saturation transfer difference nuclear magnetic resonance spectroscopy was performed with the Mannitou antigen-binding fragment. The STD-NMR data demonstrated the strongest interactions with the aliphatic protons H1 and H2 of the α 1-3-linked mannose, and weaker imprints on its H3, H4 and H5 protons. In conclusion, Mannitou IgM binding requires a non-substituted α 1,3-linked mannose branch of paucimannose also on proteins, making it a highly specific tool for the distinction of concurrent human tumor-associated carbohydrate antigens.

Running title: Binding by Mannitou IgM of paucimannose-carrying proteins

Keywords: Mannitou; IgM; PMG; PMP; paucimannose; *N*-glycan; core fucose

Introduction

The biological importance of glycosylation in health and disease has long been established and continues to grow (Lau *et al.*, 2007; Lauc *et al.*, 2010; Taganna *et al.*, 2011; Bruxelle *et al.*, 2020). The glycoproteome reflects the overall cellular status since it participates either in modulation or mediation of a wide range of processes in physiological and pathophysiological conditions, *i.e.* cell adhesion, molecular trafficking and clearance, protein folding, receptor activation, signal transduction and endocytosis (Stambuk *et al.*, 2020; Lau and Dennis, 2008). Protein glycosylation patterns are modified in various human diseases, including congenital disorders of glycosylation (Houdou and Foulquier, 2020), auto immune diseases such as rheumatoid arthritis (Magorivska *et al.*, 2018) and systemic lupus erythematosus (Szabo *et al.*, 2019), and in infectious diseases (Thaysen-Andersen *et al.*, 2015). The ubiquity of glycosylation and its fundamental significance in practically every biological process exemplifies the immense potential of glycans as biomarkers (Reily *et al.*, 2019; de Vroome *et al.*, 2018).

The core structure of all eukaryotic *N*-glycans consists of two *N*-acetyl β -glucosamine (GlcNAc) and three mannose (Man) residues, $\text{Man}_3\text{GlcNAc}_2$, also termed paucimannosidic glycan (PMG) (Schachter, 2009). The early stages of *N*-glycosylation are shared among all eukaryotes and include the generation of a lipid-linked oligosaccharide precursor $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$ -pyrophosphate-dolichol to nascent glycoproteins in the endoplasmic reticulum (Aebi *et al.*, 2010). The second phase involves the processing of asparagine-linked $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$ within the lumen of the endoplasmic reticulum up to $\text{Man}_5\text{GlcNAc}_2$ in the Golgi apparatus. This pathway diverges evolutionary in plants, invertebrates and vertebrates, that each process the $\text{Man}_5\text{GlcNAc}_2$ intermediate in different ways into high-mannose, hybrid, and complex *N*-glycans. In humans, an enzyme in the Golgi apparatus, *N*-acetyl β 1-2-glucosaminyltransferase (GnT-I), transfers a GlcNAc residue on the α 1,3-linked mannose of the *N*-glycan. Following the trimming of the α 1,6 Man arm by α -mannosidase-II, this hybrid glycan is finally truncated into a PMG by an *N*-acetyl- β -hexosaminidase (Hex A or Hex B) (Tjondro *et al.*, 2019). **An alternative, GnT-I**

1
2
3 independent, truncation pathway has been shown to facilitate greatly the biogenesis
4 of α 1,6 core-fucosylated $\text{Man}_4\text{GlcNAc}_2$ and $\text{Man}_5\text{GlcNAc}_2$ in GnT-I-deficient Chinese
5 hamster ovary cells (Lin *et al.*, 1994).
6
7

8
9 Despite the great progress achieved in the field, rapid detection of alterations
10 in the expression of specific *N*-glycans associated with pathophysiological states is
11 still challenging. Anti-carbohydrate antibodies lend a good diagnostic tool to this aim.
12 Mannitou is a monoclonal mouse IgM, originally named Laz6-189, raised against a
13 130-kDa glycoprotein from the leech central nervous system (Flaster *et al.*, 1983). It
14 was subsequently characterized as being able to specifically recognize
15 paucimannose-carrying glycoproteins (PMPs) (Bajt *et al.*, 1990; Zipser *et al.*, 2012).
16 Since, other PMPs with important neurobiological functions have been detected using
17 Mannitou, among others human neutrophil elastase (Loke *et al.*, 2017), synapsin-1
18 (Simon *et al.*, 2019) and AHNAK (Becker *et al.*, 2019). Intriguing recent discoveries
19 point to paucimannose *N*-glycans (PMGs) as facilitators of an effective immune
20 response during physiological and pathophysiological conditions (Loke *et al.*, 2016).
21
22

23
24 A recent wide cancer glycomics analysis from human cancer cell lines and
25 tissue samples illustrated that different cancer types and the disease progression
26 stage can be stratified based on the distribution and ratios of paucimannosidic *N*-
27 glycans (Chatterjee *et al.*, 2019). Both the rare incidence of paucimannose *N*-
28 glycosylation in the extracellular environment and its upregulation to give potent
29 signals and communicate with the immune system have made Mannitou a useful tool
30 for the detection of paucimannose epitopes (Chatterjee *et al.*, 2019; Becker *et al.*,
31 2019; Dahmen *et al.*, 2015; Thaysen-Andersen *et al.*, 2015; Loke *et al.*, 2017; Zipser
32 *et al.*, 2012; Simon *et al.*, 2019). Paucimannose-carrying proteins are exposed on the
33 plasma membrane of transforming cells as opposed to high-mannose-carrying
34 proteins predominantly hidden in the cytoplasm of normal cells (Loke *et al.*, 2016),
35 enabling their targeting by monoclonal antibodies such as Mannitou IgM. In this study,
36 we highlight interaction regions on the $\text{Man}_3\text{GlcNAc}(\text{Fuc}\alpha 1-6)\text{GlcNAc}$ PMG with
37 paratope residues of the Mannitou variable domains and demonstrate how specificity
38 and affinity of Mannitou is fine-tuned to differentiate between paucimannosidic and
39 other *N*-glycans on proteins.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results


Ligand screening with microarrays of defined paucimannose N-glycans

Initially, the characterization of carbohydrate binding profile of Mannitou IgM was performed with the help of glycan microarrays, a technique that enables the high-throughput screening of protein-carbohydrate interactions. Mannitou IgM was assayed against a microarray consisting of 135 different glycan structures (Figure S1), among which multiple paucimannose-type *N*-glycans.

This glycan microarray has been exploited previously to quantify the immune response against *S. mansoni* parasitic infection (Nkurunungi *et al.*, 2019) and therefore, the glycans included comprise structures from non-mammalian origin commonly found in invertebrates and plants with substitutions such as core α 1,3 fucose (Fuc) and β 1,2 xylose (Xyl) (Brzezicka *et al.*, 2015). Two-fold serial dilutions of Mannitou IgM (500, 250, 125 and 62.5 nM) were incubated on the microarray at RT for one hour and interactions were revealed with Alexa Fluor 555 Goat Anti-Mouse IgM secondary antibody (Figure S2A). Previously, Mannitou antibody has been screened against the glycan array 4.0 of the Consortium for Functional Glycomics and demonstrated a highly restricted specificity for the Man₃GlcNAc₂ pentasaccharide (Zipser *et al.*, 2012) and any substitution inhibited or significantly reduced binding. In line with these previous findings, our results show that Man α 1-3(Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc (GL41), being the common pentasaccharide core M3GN2 of all *N*-glycans, displays one of the highest RFU values. Nevertheless, in our experiment, Mannitou binding was not exclusive for this core structure and different printed glycans exhibited important recognition (Figures 1 and S2B).

The main conclusions drawn from the microarray screening is that the printed structures efficiently recognized by Mannitou all have in common an unsubstituted mannose (also called residue 4 in high-mannose-type oligosaccharides, lacking substitution by α 1,2-linked mannoses C and D1 (Kozutsumi *et al.*, 1986)) of the α 1,3 branch in the *N*-glycan core. All substitutions on the α 1,3 Man arm either with Man α 1-2 (GL42) or with GlcNAc β 1-2 (GL55) completely abolished Mannitou IgM binding (Figure 1A). On the other hand, the substitution with core α 1,6-fucose in Man₃ *N*-

glycan (GL70) showed similar RFU values to the non-fucosylated structure (GL41). In fact, Man α 1-3Man β 1-4GlcNAc β 1-4GlcNAc (GL40), a dimannose-containing *N*-glycan lacking the α 1,6 Man arm, and its β 1,2 xylosylated counterpart (GL2) were also recognized, albeit with much lower intensity than their Man3 equivalent (respectively GL41 and GL7, Figures 1A and S2). On the other hand, the sole α 1-6-linked dimannose-containing structure Man α 1-6(Xyl) β 1-2Man β 1-4GlcNAc β 1-4GlcNAc (GL1) did not bind (Figure S2), despite the absolute tolerance for β 1,2 xylosylation on the central mannose of the *N*-glycan, thus confirming the specificity of Mannitou IgM towards the nature of the α 1,3 glycosidic linkage.



For Man α 1-3(Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc (**GL41**) and Man α 1-3(Man α 1-6)Man β 1-4GlcNAc β 1-4(Fuc α 1-6)GlcNAc (**GL70**), apparent equilibrium dissociation constants (K_{dsurf}) on the microarray surface were calculated by plotting the fluorescence intensities (relative fluorescence units, RFU) against the antibody concentrations and fitting the data to a one-site binding Langmuir isotherm (Liang *et al.*, 2007). Both glycans showed apparent dissociation constants in the **submicromolar** range (Figure 1B).




Figure 2. Dual color heat map representation of the normalized glycan microarray binding profiles of **Mannitou**, **Concanavalin A (ConA)** and **Galanthus nivalis agglutinin (GNA)**. Hierarchical clustering is based on Euclidean distance (average linkage method). For glycan structures, see Figure S1.

The binding pattern of Mannitou IgM on the glycan microarray was compared with those of other mannose-binding lectins, namely concanavalin A (*Canavalia*

1
2
3 *ensiformis* agglutinin, ConA) and *Galanthus nivalis* agglutinin (GNA) (Figure 2). A heat
4 map allows to compare the performance of Mannitou IgM with the two lectin lectins to
5 define the most suitable probe for applications. From all structures available in the
6 glycan array, only paucimannose, high mannose and hybrid type structures are
7 represented in the heat map. Although ConA, GNA and Mannitou all recognize
8 mannose, important differences between the three proteins are highlighted (Figure 2).
9 All recognition probes bind M3GN2 and M5GN2 N-glycan structures efficiently, but
10 Mannitou recognized Xyl β 1-2-substituted M3GN2 N-glycans much more efficiently
11 than ConA while GNA showed no binding to these structures (Brzezicka *et al.*, 2015).
12 Additionally, both ConA and GNA bind to several high mannose and hybrid type
13 structures (e. g. **GL65**, **GL54**, **GL45**) which are not recognized by Mannitou antibody.
14 These results highlight the importance of defining in a precise manner the binding
15 epitopes for the different carbohydrate-binding proteins.
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Based on the microarray screening results and on the reported paucimannose
30 type structures described in pathological processes (Becker *et al.*, 2019; Chatterjee
31 *et al.*, 2019), M3GN2 (**GL41**) and the corresponding α 1-6 core-fucosylated structure
32 M3GN2F1(6) (**GL70**), were selected and synthesized chemo-enzymatically (Figure
33 S3) in sufficient amounts for subsequent Surface Plasmon Resonance (SPR) kinetic
34 binding experiments and Saturation Transfer Difference-Nuclear Magnetic
35 Resonance (STD-NMR) structural analyses.
36
37
38
39
40
41
42

43 ***Molecular recognition studies of paucimannose N-glycans by Mannitou IgM***

44 Mannitou IgM could be purified using size-exclusion chromatography due to its
45 large molecular mass (Figure S4). The next steps involved investigating the molecular
46 recognition of paucimannose N-glycans by Mannitou IgM. We deciphered their
47 specificity for Mannitou IgM by determining the kinetic parameters of binding using
48 SPR detection (Figure 3). The synthetic M3GN2 (**GL41**) was immobilized on a CM5
49 sensor chip, as it was the minimal epitope to Mannitou IgM, and M3GN2F1(6) (**GL70**)
50 on the same chip to run the microfluidics experiment under exactly the same
51 conditions. N-glycan core α 1-6-linked fucose is an important residue in carbohydrate-
52 carbohydrate interactions, involved in complement activation and antibody-mediated
53
54
55
56
57
58
59
60

cellular cytotoxicity (Ferrara *et al.*, 2011; Sakae *et al.*, 2017). While β 1,2-linked xylose and α 1,3-linked fucose are immunogenic *N*-glycan motifs from plants and invertebrates but absent in mammals (Brzezicka *et al.*, 2015), in mammals core fucose is found exclusively as α 1-6-linked to the reducing-end *N*-acetylglucosamine (GlcNAc) moiety of the chitobiose core (Serna *et al.*, 2011).




Figure 3. Kinetic binding experiments of Mannitou IgM to immobilized PMGs

SPR sensorgrams of a concentration series (0.08 – 336 nM, coloured lines) of the IgM and fitting (black lines) to a 1:1 Langmuir binding model. (A) Fc2-Fc1 difference sensorgrams with $\text{Man}_3\text{GlcNAc}_2$ immobilised on Fc2. (B) Fc4-Fc3 difference sensorgrams with $\text{Man}_3\text{GlcNAc}_2(\alpha$ 1-6)Fuc immobilized on Fc4. Fc1 and Fc3 are blank CM5 channels. Full regeneration between cycles was obtained using 50 mM NaOH. RU: Response Units.

Mannitou IgM binds with a very fast, concentration-dependent, *on*-rate ($k_{\text{on}}=k_a[\text{C}]+k_d$) to these PMGs together with rather large dissociation rate ($k_{\text{off}}=k_d$). (Table I). Such kinetics of binding are most likely helped by the dense immobilization of the glycans and re-binding effects. Indeed, only a small portion of bound IgM “sticks” and maintains a stable interaction (Figure 3). Nanomolar affinities are obtained, with no significant difference between M3GN2 and M3GN2F1(6). We next wanted to gain insight into the influence of the presentation of PMG epitopes onto proteins, paucimannose-carrying proteins or PMPs.

Ligand	Imm. RU	R_{max} RU	SE(R_{max}) RU	k_a $\text{M}^{-1}\cdot\text{s}^{-1}$	SE(k_a) $\text{M}^{-1}\cdot\text{s}^{-1}$	k_d s^{-1}	SE(k_d) $\text{M}^{-1}\cdot\text{s}^{-1}$	K_d nM	SE(K_d) nM	Chi ²
M3GN2	237	132.5	0.5	300816	2142	2.07E-03	1.72E-05	6.87	0.08	26.86
M3GN2F1(6)	163	28.7	0.2	470885	6304	2.77E-03	3.51E-05	5.87	0.11	4.33

Table I: Immobilization rate and fitted global parameters for the kinetics of PMG binding by Mannitou IgM

SE: Standard Error. RU: Response Units.

Glycoprotein differentiation by Mannitou IgM

Mannitou IgM was allowed to interact with differently glycosylated forms of omega-1 (ω 1) (van Noort *et al.*, 2020) and kappa-5 (κ 5) (Wilbers *et al.*, 2017), two major immunomodulatory *Schistosoma mansoni* soluble egg antigens. Mannitou IgM interacted with the omega-1 glycoproteins with much lower *on*- rates but also smaller *off*-rates than for PMGs alone (Table II). This could be explained because only two glycosylation sites are present per omega-1 protein, thus the density of PMG immobilization is much lower. Another difference is that the dextran matrix was completely shielded from interaction with Mannitou IgM by the high protein immobilization rate (Figure 4). The high-mannosylated glycoform of κ 5 (Figure S5) was found not to be bound by Mannitou IgM and it was therefore used to block aspecific binding in the reference flow channel. Regeneration between the different analyte concentrations was avoided because the paucimannose-carrying glycoproteins (PMP) could be damaged using harsh eluents, instead, a single cycle kinetic titration was used. The Mannitou IgM analyte was titrated at five different concentrations, from low (59.4 nM) to high (950 nM).

Ligand	Imm. RU	R _{max} RU	SE(R _{max}) RU	k _a M ⁻¹ .s ⁻¹	SE(k _a) M ⁻¹ .s ⁻¹	k _d s ⁻¹	SE(k _d) M ⁻¹ .s ⁻¹	K _d nM	SE(K _d) nM	Chi ²
ω 1 M3GN2	2324	66.4	1.5	3629	187	3.82E-4	8.25E-06	105	6	4.96
ω 1 M3GN2F1(6)	2061	68.0	2.2	4056	298	3.10E-4	1.11E-05	76.5	6.3	16.02
ω 1 M3GN2F1(3)	2505	28.8	1.4	4374	388	4.67E-4	1.84E-05	107	10	11.56
ω 1 M5GN2 & Le ^x	3271	32.9	3.6	7088	1181	5.78E-4	5.53E-05	81.6	15.7	14.38

Table II: Immobilization rate and fitted global parameters for the kinetics of PMP binding by Mannitou IgM

SE: Standard Error. RU: Response Units.




Figure 4. Kinetic binding experiments of Mannitou IgM to immobilized PMPs

Single cycle kinetics, or kinetic titration, of Mannitou IgM onto different PMPs, of which the major glycoform(s) is/are shown(n) in the inset (see experimental procedures for full details). Sensorgrams (red) after subtraction of non-binding kappa-5 M7GN2/M8GN2, see Figure S5) in Fc1 and fitting (black) according to a 1:1 Langmuir binding model. (A) ω 1 M3GN2, (B) ω 1 M3GN2F1(6), (C) ω 1 M3GN2F1(3), (D) ω 1 M5GN2 + Le^x. RU: Response Units.

Affinities (K_d) fit near 100 nM, with a small favour of Mannitou IgM for ω 1 M3GN2F1(6) and M5GN2 (Table II and Figure 5). For another omega-1 PMP glycan-engineered with a single Le^x epitope (second *N*-glycan shown in Figure 4D) as the major glycoform (Wilbers *et al.*, 2017), no binding was detected using SPR. In line with this observation, Le^x epitopes presented on the glycan microarray (e. g. **GL91** and **GL92**) were not recognized by Mannitou IgM (Figure S2A). Therefore, the affinity for omega-1 presenting mixed major glycoforms of M5GN2 and Le^x (Figure 4D) could be most probably attributed to oligomannose-5 binding. This finding is again congruent with the results of IgM binding to M5GN2 (**GL43**) of the glycan microarray (Figure 1A). Possibly, the binding of M5GN2 (**GL43**) is a little stabilized over M3GN2 (**GL41**) consistently between microarray screening and SPR measurements (Table II) and judged based on the maximal binding capacity (R_{max}) and affinity (Figure 5).




Figure 5. Comparison of PMP with PMG binding of Mannitou IgM

Maximal binding (R_{max} , light grey) and affinities (K_a , dark grey) of Mannitou IgM analyte for the two M3GN2 and M3GN2F1(6) PMG ligands, coupled via the amino-pentyl spacer at their reducing end on the sensor chip (Figure S3), and comparison with their presentation as asparagine-linked *N*-glycans on the immobilized omega-1 proteins.

Epitope mapping by STD-NMR spectroscopy

STD-NMR spectroscopy is often used to determine molecular surface patches/regions on glycan epitopes that are directly involved in binding proteins such as lectins and carbohydrate-binding antibodies (Arda and Jimenez-Barbero, 2018; Henriques *et al.*, 2020). In spectra collected in aqueous, i.e. polar, buffers, only aliphatic and aromatic epitope proton resonances are visible, while the polar/acidic set of H atoms in glycans (those that are part of hydroxyl, amine and carboxy groups) rapidly exchange with the surrounding solvent molecules (Blaum *et al.*, 2018).

For the STD-NMR experiments, the antigen-binding fragment (Fab) of Mannitou was generated by transient transfection in mammalian HEK293^T cells and purified using nickel affinity chromatography (Figure S6A). A mammalian expression system was chosen because it allows an efficient post-translational processing in the secretory pathway that is vital for the correct folding of antibodies and its fragments

(Aricescu *et al.*, 2006). The bioactivity of Mannitou Fab was verified prior to STD-NMR experiments by means of SPR that followed complex formation of the Fab with immobilized ω -1 M3GN2 (Figure S6B). The observed fast *on*- and *off*-rates indicated it to be in the right range of affinity for STD-NMR measurements to be feasible.




Figure 6. PMG epitope for Mannitou antibody based on ^1H -STD-NMR spectroscopy

^1H -STD experiments for Mannitou Fab (25 μM) with glycan epitope (1 mM) **(A)** Man₃GlcNAc₂ and **(B)** Man₃GlcNAc₂Fuc. In **(A)**, protons of the glycan giving STD signals are labeled (black). Stars (*) indicate potentially overlapping protons from the α 1-3- and α 1-6-linked mannose. Protons that do not give any STD (non-overlapping) signals are labeled (grey) in the reference spectrum. A 3D-structural model of the interaction regions (indicated by thick grey lines) of M3GN2F1(6) was derived from the STDDD spectrum (top) and the off-resonance spectrum (bottom). It can be seen that the STDDD spectra in **(A)** and **(B)**, respectively without and with the α 1-6 core fucose, are almost identical.


¹H-STD NMR experiments were performed using the same two PMGs selected from the microarray screening (Figure 6). The STD spectra at the aliphatic and the aromatic irradiation frequencies for the non-fucosylated M3GN2 (**GL41**) (Figure 6A) and fucosylated M3GN2F1(6) (**GL70**) (Figure 6B) were essentially the same. All protons belonging to the α 1-3-linked mannose gave STD signals, where H1 and H2 were the protons with the strongest STD effect. The same protons from the mannose on the α 1,6 arm demonstrated no STD effect. In addition, there was a very weak STD effect of H2 of the central β Man residue and a weak STD signal of the acetyl (Ac) group on the GlcNAc1 residue (Figure 6).

In the more crowded region of 3.6 - 3.9 ppm, an STD effect is also observed for H3, H4 and H5 protons of the α Man residue. These protons resonate at the same frequency for α 1,6 and α 1,3-linked mannose, however, the above-mentioned results involving H1 and H2 suggest that they correspond to the α 1,3-linked mannose. The protons of GlcNAc2 exhibited no STD effect, in contrast to the protons on the acetyl (Ac) group of the reducing end GlcNAc (GlcNAc1). This probably results from the conformation of the PMG in the protein-bound form, where the acetyl group of GlcNAc1 points to the same side as the α 1,3-linked mannose, while the one of GlcNAc2 points in the opposite direction (Figure 6).

A molecular model for Mannitou Fab in complex with its minimal epitope

Molecular docking simulations indicate that the M3GN2 (**GL41**) PMG epitope occupies a binding site shaped by Complementary Determining Region (CDR) loops as predicted using the Paratome program (Kunik *et al.*, 2012) on the sequence of Mannitou Fab. The amino acid sequences of the purified IgM were for the large majority covered using MALDI-TOF MS peptide fingerprinting within a 1% precision *m/z* rate and confirmed the full presence of the heavy and light chains of Mannitou IgM (Figure S7). Prediction of the binding mode of M3GN2 onto the homology model of Mannitou Fab shows the α 1-3-linked mannose inserted in a snug pocket on the protein surface, between Trp33 and Tyr104 respectively belonging to the heavy chain CDR1 and CDR3 (Figure 7). Running a docking simulation with the α 1-6 core-fucosylated PMG, M3GN2F1(6) (**GL70**), does not change this pattern of binding.

1
2
3 However, as soon as an additional residue is substituted onto the α 1-3-linked
4 mannose, this interaction with Mannitou Fab is impeded. This is congruent with what
5 was observed in the microarray study and is presumably due to the complementary
6 shape of the cavity, where a substitution on the axial 2-position of the α 1-3-linked
7 mannose of M3GN2 may force it to leave its snug pocket.
8
9
10
11
12



36 **Figure 7. Positioning of M3GN2 into the Mannitou Fab homology model**

37 Molecular docking between the Mannitou Fab 3D-model and Man₃GlcNAc₂ demonstrates the docking of the α 1-3
38 mannose into a snug pocket. Residues are colored according to the CDR they belong to and identically as depicted
39 on the sequenced IgM (Figure S7). Molecular presentation prepared using The PyMOL Molecular Graphics
40 System, Version 2.0, from Schrödinger, LLC.
41
42
43
44
45

46 Discussion

47
48
49
50 The biological importance of glycosylation in physiological and
51 pathophysiological conditions is broadly acknowledged. Human protein
52 paucimannosylation characterization was pioneered by the group of Nicola Parker,
53 who discovered an unconventional form of α - and β -mannose epitope-rich human *N*-
54 glycosylation, on proteins in sputum from inflamed and bacteria-infected individuals
55 (Thaysen-Andersen *et al.*, 2015; Venkatakrishnan *et al.*, 2015). Namely neutrophil
56
57
58
59
60

1
2
3 elastase, proteinase 3 and cathepsin G had been reported earlier to be abundantly
4 enriched in paucimannose on the plasma membrane of human neutrophils upon their
5 activation (Campbell and Owen, 2007) and had been held responsible of driving
6 cluster formation on the neutrophil cell surface (Hajjar *et al.*, 2008). Mammalian PMP
7 biogenesis has a hexosaminidase-dependent pathway, where an N-acetyl- β -
8 hexosaminidase trims immature complex *N*-glycans retroactively down to PMGs
9 (Tjondro *et al.*, 2019). This same strategy we have applied in the chemo-enzymatic
10 synthesis of M3GN2F (Figure S3).
11
12

13
14
15
16
17
18 Human PMG products of the hexosaminidase activity were recently
19 characterized by quantitative proteomics (Chatterjee *et al.*, 2019). The thus truncated
20 α -mannose-terminating structures spanned the monosaccharide compositions of
21 [Man₁₋₃GlcNAc₂ Fuc₀₋₁] on human paucimannose-carrying proteins (PMPs), with a
22 prevalence of one of the two dimannose isomers, namely
23 Man α 1,6Man β 1,4GlcNAc β 1,4(Fuca1,6)GlcNAc β Asn. Unsubstituted Man α 1-6Man
24 PMG was not printed on the glycan array (Figure S1) and the latter only contains the
25 dimannose Man α 1-6Man with a β 1,2-linked xylose substitution on the central β Man
26 (**GL1**) (Figure S1A). Dimannose **GL1** with α 1,6 mannose residues, but lacking α 1,3
27 residues, does not show any binding to Mannitou IgM, while **GL4**, with a GlcNAc
28 extension on the α 1,6 Man arm is tolerated and demonstrates binding to Mannitou
29 (Figure S2). The binding of the **GL1** glycan can be directly compared with the Man α 1-
30 3Man dimannose equivalent, **GL2**. **GL2**, **GL8** and **GL40** are all Man α 1-3Man
31 dimannose PMGs with similar weak binding signals, whereas the M3GN2 structures
32 **GL7** and **GL41** showed strong binding to Mannitou IgM, independent of the presence
33 of β 1,2-linked xylose on the central mannose. For **all** these reasons, the absence of
34 signal for the α 1-6-linked dimannose PMG (**GL1**) was interpreted to be due to non-
35 binding of the α 1,6-arm and this *N*-glycan was not included in subsequent analyses.
36 Among other PMGs found in human paucimannosylation, M1GN2 (**GL39**) displaying
37 a single mannose residue, did also not bind Mannitou IgM (Figure S2A).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54
55
56
57
58
59
60
Mannitou only displays significant affinities from oligomannose-3 on,
represented by the minimal epitope M3GN2. Measured affinities are near 100 nM (K_d)
both in glycan array and SPR experiments (Figure 1B and Table II). ¹H-STD NMR
experiments were performed using two PMGs selected from the microarray screening.

1
2
3 Non-fucosylated M3GN2 (**GL41**) (Figure 6A) and fucosylated M3GN2F1(6) (**GL70**)
4 (Figure 6B), PMG epitopes for Mannitou Fab, displayed very similar STDDD spectra
5 in which the same protons showed analogous ¹H-STD NMR effects. The two epitopes
6 are thus estimated the same. What is more, the intensities of their STD signals were
7 the same, which indicates that their interactions are also the same in terms of affinity.
8 Likewise, when printed on the microarray (Figure 1), immobilized on the SPR sensor
9 chip (Table I) or presented on one of the omega-1 glycosylation sites (Table II), there
10 appears no significant difference in affinity between the two PMGs (Figure 5). That
11 suggests that no hindrance, nor significant contribution to affinity, is made by the
12 fucose α 1,6-linked to the core GlcNAc1 (Figure 6). It has been described that core
13 fucose may lead to a different presentation of the *N*-glycan and introduce dynamics in
14 the glycan chain (Sakae *et al.*, 2017). Yet, the presence of the α 1-6-linked core fucose
15 does not hinder binding to Mannitou, which is a positive point for the use of the
16 antibody in diagnosis of PMGs and PMPs, as M3GN2 and M3GN2F1(6) were both
17 found to be very important PMGs in human cancer samples (Chatterjee *et al.*, 2019).
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 STD-NMR spectroscopy revealed that the protons strongest implicated in
33 interactions with Mannitou were H1 and H2 on the α 1,3-linked mannose, with weaker
34 signals from the other protons of the same arm, from the H2 proton of the central
35 β Man and from the acetyl group of GlcNAc1 at the reducing end of the *N*-glycan
36 (Figure 6). Interestingly, the STDDD spectra at the aliphatic and the aromatic
37 irradiation frequencies were essentially identical. Coherent with the ¹H-STD NMR
38 measurements, molecular simulations indicate that Man α 1-3 might dock into a pocket,
39 or hydrophobic groove, formed by aromatic residues of the predicted CDR loops of
40 the Mannitou Fab (Figure 7). These conclusions are fully in line with the results from
41 the microarray and from the docking, which showed that any substitution at the 2-
42 position of α Man on the α 1,3 Man arm, either with Man α 1-2 (**GL42**) or with GlcNAc β 1-
43 2 (**GL55**), abolishes binding (Figure 1A). Once the requirement of the unsubstituted
44 α 1,3 Man arm is fulfilled, the substitution of the α 1,6 Man arm showed an important
45 permissiveness in the structure (**GL23, GL27, GL34**, Figure S2). Additionally, different
46 non-mammalian substitutions such as core Xyl β 1-2 (**G2, G7**, Figure S2), core Fuca1-
47 3 (**G72, G90**, Figure S2) and core-bis fucosylation (**GL10, GL75**, Figure S2) did not
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 impede binding. As these structures are not part of the mammalian glycome, they
4 were not considered for further studies, but this data could open new applications of
5 Mannitou antibody in invertebrate and parasitic glycomic studies.
6
7
8
9

10 Among the high-mannose structures printed, only Man5 *N*-glycan (**GL43**,
11 Figure 1A) and core fucose substituted Man5 *N*-glycans (**GL74**, **GL134** in Figure S2B)
12 were recognized by the antibody efficiently. Considering these results, there is a
13 quantitative difference in recognition between our screening and previously published
14 data (Zipser *et al.*, 2012), where on the glycan array from the Consortium for
15 Functional Glycomics a small fluorescence signal was detected for pentamannose
16 (Man5, without the chitobiose core) and only a very minor fluorescence signal for
17 M5GN2. The Man5 *N*-glycan M5GN2 (**GL43**) was therefore previously described to
18 have only a residual binding towards Mannitou antibody, while in our data it was
19 recognized at least as efficiently as M3GN2 (**GL41**). For the same PMGs presented
20 on a glycoprotein, omega-1 M5GN2 & Le^x, a similar affinity was observed as for
21 omega-1 M3GN2 (Table II, Figure 5). Glycan densities may play an important role in
22 the binding of the multivalent IgM, and we also observed this effect using SPR in a
23 significantly higher affinity for PMGs, that were much more densely immobilized, than
24 for PMP binding (Figure 5). It is perhaps not so surprising for carbohydrate-binding
25 proteins specific for the α 1,3 Man arm of the *N*-glycan core structure to have a
26 tolerance for substitutions on the α 1,6 Man arm. It is not unusual either, for instance
27 a similar non-distinction between M3GN2 and M5GN2 has been found for the FimH
28 lectin from *Escherichia coli* (Bouckaert *et al.*, 2006). In contrast, the kappa-5
29 glycoprotein carrying predominantly M7GN2 and M8GN2 (Figure S5) did not bind
30 Mannitou IgM and for this reason it was used as the baseline reference in the SPR
31 experiments (Figure 4). In conclusion, our results indicate that Mannitou antibody has
32 submicromolar affinities also for oligomannose-5 *N*-glycans, that are generally not
33 called paucimannosidic.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Alpha-mannose determinants are relative rare glycan-epitopes in physiological
56 extracellular environments (Dahmen *et al.*, 2015), but may be actively secreted or
57 leaked from cells to transmit potent signals when required (Thaysen-Andersen *et al.*,
58
59
60

2015; Loke *et al.*, 2017). Our understanding of the role of these signals in mounting an effective immune response during physiological and pathophysiological conditions is rapidly advancing. The functional implications of Mannitou IgM binding M3GN2 and M5GN2 epitopes will likewise need to be further addressed. In conclusion, our multidisciplinary approach of the molecular recognition of paucimannose *N*-glycans by Mannitou antibody by glycan microarrays, SPR, STD-NMR, modelling and docking allowed to pinpoint the minimal epitope-determining regions of the glycan and shed light on the paratope of Mannitou. Our study highlights the rationale for the “forbidden” substitution on the α 1,3-linked mannose branch of the *N*-glycan pentasaccharide core Man3GlcNAc2. Gaining a better structural insight into the selectivity of the monoclonal antibody warrants to improve its diagnostic qualities in specifically targeting distinct types of paucimannosylation.

Materials and Methods

Gene sequencing of Mannitou IgM

The genomic sequences of the variable domains (VL and VH) of Mannitou antibody were determined by Fusion Antibodies Ltd (Belfast, Northern Ireland) by mRNA extraction from hybridoma cells (Laz6-189/Mannitou mAb available from the DSHB, deposited by B. Zipser) and cDNA synthesis by RT-PCR. The positive PCR products were identified by agarose gel electrophoresis and sequenced on an ABI3130xl Genetic Analyzer (Applied Biosystems).

Mannitou IgM expression, purification and variable region sequence analysis

In order to produce Mannitou IgM, hybridoma cells were cultured in serum-free medium (SFM) for three weeks and allow to secrete mAb in the medium. Subsequently, the supernatant was recovered and the Mannitou IgM was purified using a HiLoad™ 16-600 Superose™ 6 prep grade size exclusion chromatography column on an ÄKTA Pure (Cytiva). The running buffer consisted of 0.2 M sodium bicarbonate at pH = 8 and 0.5 M NaCl. The separation was carried out at a maximum flow rate of 0.5 ml/min.

1
2
3 Peptide mass fingerprinting using MALDI-TOF was performed upon in-gel
4 digestion of Mannitou IgM using trypsin. The protein bands for heavy and light chain
5 were excised and subjected to an in-gel digestion protocol consisting of dithiothreitol
6 reduction at 56°C (10 mM, 20 min), followed by iodoacetamide alkylation (55 mM, 20
7 min in a dark environment) and finally trypsin incubation (12.5 µg/µL) overnight at
8 37°C. After digestion, peptides were extracted with ammonium bicarbonate (25 mM)
9 and trifluoroacetic acid (0.1% in water). The sequences for the variable domains were
10 uploaded in the data base together with the constant regions (UniProtKB P01872 or
11 entry IGHM_MOUSE for the heavy constant µ chain, P01837 or entry IGKC_MOUSE
12 for the light κ constant domain) to enable proteomics analysis of the peptide mass
13 fingerprinting MALDI-TOF spectrometric data. The Complementarity Determining
14 Regions or CDRs were predicted using the program Paratome (Kunik *et al.*, 2012) and
15 glycosylation was predicted based on programs NetNGlyc (Gupta and Brunak, 2002)
16 and NetOGlyc (Steentoft *et al.*, 2013).

27 **Microarray preparation and screening with Mannitou IgM and plant lectins**

28
29
30 The glycan microarrays were prepared as described earlier (Brzezicka *et al.*,
31 2015). Briefly, 50 µM ligand solutions (1.25 nL, 5 drops, 250 pL drop volume) in
32 sodium phosphate buffer (300 mM, 0.005% Tween-20, pH=8.4) were spatially arrayed
33 employing a robotic non-contact piezoelectric spotter (SciFLEXARRAYER S11,
34 Scienion) onto *N*-hydroxysuccinimide (NHS) activated glass slides (Nexterion H,
35 Schott AG). After printing, the slides were placed in a 75 % humidity chamber for 18
36 hours at 25°C. The remaining NHS groups were quenched with 50 mM solution of
37 ethanolamine in sodium borate buffer (50 mM, pH=9.0) for 1h. The slides were
38 washed with PBST (PBS/0.05% Tween-20), PBS and water, then dried in a slide
39 spinner and stored at -20°C until use. Mannitou monoclonal antibody, **secreted by the**
40 **hybridoma cells in the serum-free medium**, was diluted to approximately 25 µg/mL in
41 PBS (1% BSA, 0.01% Tween-20). The antibody solution (200 µL) was incubated on
42 the microarrays for 1h at RT. The slides were washed with PBST and PBS. Next, they
43 were incubated with Alexa Fluor 555 Goat Anti-Mouse IgM (1:1000) (Thermo Fischer
44 Scientific) in PBS (1% BSA, 0.01% Tween-20) for 1 h in the dark. The microarrays
45 were washed from the unbound secondary antibody with PBST, PBS and water.
46 Solutions of fluorescently labelled ConA-555 (10 µg/mL) and GNA-555 (25 µg/mL) in
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 TSM buffer (Tris 25 mM, 150 mM NaCl, pH=7.5) containing 2 mM CaCl₂ and 2 mM
4 MgCl₂ were incubated in the glycan microarray at RT for 1 hour in the dark. The slides
5 were washed with TSM buffer containing 0.01% Tween-20 and water. Slides were
6 subsequently dried in a slide spinner dried. The fluorescence measurements were
7 performed on Agilent G2565BA Microarray Scanner (Agilent Technologies) at 10 μm
8 resolution. The quantification of fluorescence was done using ProScanArray Express
9 software (Perkin Elmer) employing an adaptive circle quantification method from 50
10 μm (minimum spot diameter) to 300 μm (maximum spot diameter). Average RFU
11 (Relative Fluorescence Unit) values with local background subtraction of four spots
12 and standard deviation of the mean were reported using Microsoft Excel and
13 GraphPad Prism software.
14
15
16
17
18
19
20
21
22
23
24

25 **Synthesis of M3GN2 and M3GN2F1(6) paucimannosidic glycans**

26 M3GN2 (**GL41**) and M3GN2F1(6) (**GL70**), each figuring an amino-pentyl
27 spacer at their reducing end (Figure S3), were prepared using a modular synthesis
28 starting from biantennary G₀, as described earlier (Serna *et al.*, 2010). Core (α1-6)
29 fucosylation on G₀ (5.2 mg, 3.68 μmol) was effected using the GDP-fucose (3.3 mg,
30 5.52 μmol) donor and the *Anopheles gambiae* FUT6 enzyme (Serna *et al.*, 2013) in
31 MES buffer (80 mM, pH=6.5) including MnCl₂ (20 mM), by stirring at RT until complete
32 consumption of the starting material. Next, core (α1-6) fucosylated G₀ was treated
33 with β-N-acetylglucosaminidase from *Streptococcus pneumoniae* (New England
34 Biolabs) in sodium acetate buffer (50 mM, pH=5.5) including CaCl₂ (5 mM) at 37°C
35 until complete consumption of the starting material. The crude product was purified on
36 Bond Elute carbon graphitized cartridges (Agilent) to yield 2.0 mg
37 Man3GlcNAc(Fucα1-6)GlcNAc (1.76 μmol) or a 48% yield over the two steps (Figure
38 S3): ¹H NMR (500 MHz, D₂O) δ 5.12 (d, *J* = 1.7 Hz, 1H), 4.93 (d, *J* = 1.6 Hz, 1H), 4.91
39 (d, *J* = 4.0 Hz, 1H), 4.68 (d, *J* = 7.9 Hz, 1H), 4.51 (d, *J* = 8.1 Hz, 1H), 4.27 (d, *J* = 1.9
40 Hz, 1H), 4.14 (q, *J* = 6.8 Hz, 1H), 4.08 (dd, *J* = 3.4, 1.5 Hz, 1H), 3.98 (dd, *J* = 3.4, 1.7
41 Hz, 1H), 3.97 – 3.56 (m, 30H), 3.05 – 2.94 (m, 2H), 2.11 (s, 3H), 2.04 (s, 3H), 1.73 –
42 1.55 (m, 4H), 1.47 – 1.35 (m, 2H), 1.24 (d, *J* = 6.6 Hz, 3H). The HRMS (MALDI-TOF)
43 *m/z* [M+Na]⁺ calculated for C₄₅H₇₉N₃NaO₃₀ 1164.4646, was found to be 1164.4664.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PMG - Mannitou IgM kinetics of binding detected using SPR

The chip for the multi-cycle analysis using Mannitou IgM was prepared by direct immobilization of Man₃GlcNAc₂ (**GL41**) and Man₃GlcNAcFuc1 (**GL70**). Man₃GlcNAc₂ was covalently immobilized via amine coupling at 237 RU (237 pg ligand/mm² sensor surface) in Fc2 and Man₃GlcNAc₂Fuc1 at 163 RU in Fc4 on a CM5 sensor chip using 10 mM NaAc at pH=4.5 as immobilization buffer. Fc1 and Fc3 were blocked immediately after activation and served as reference surfaces. The binding interaction was studied using increasing concentrations of Mannitou mAb (0 nM, 0.8 nM, 0.16 nM, 0.33 nM, 0.66 nM, 1.31 nM, 2.63 nM, 5.25 nM, 10.5 nM, 21 nM, 42 nM, 84 nM, 168 nM, 336 nM) in 200 mM NaHCO₃, 500 mM NaCl, pH=7.8 buffer, at a flow rate of 30 μ l/min at 10°C. Each sample injection (1 min contact time, 6.5 min dissociation time) was followed by a regeneration using with 50 mM NaOH.

PMP - Mannitou interactions and affinities using SPR detection

Glyco-engineered omega-1 (ω 1, UniProt Q2Y2H4) helminth glycoproteins were plant-produced in *Nicotiana benthamiana* and purified using cation exchange chromatography, as described previously (Wilbers *et al.*, 2017). The sensor chip for single-cycle analysis using Mannitou IgM was prepared by immobilizing Δ XT/FT ω 1 carrying predominantly the carrying the *N*-glycan of choice. 10 μ g/ml of glycoprotein was covalently immobilized via amine coupling in 10 mM NaOOCCH₃ at pH = 4.5. M3GN2 was immobilized at 2300 RU (2300 pg PMG/mm² sensor surface) in Fc2, ω 1 M3GN2F1(6) at 2000 RU in Fc3, and ω 1 M3GN2F1(3) at 2500 RU in Fc4. For these PMPs, MALDI-TOF glycosylation profiles are available respectively from Figures 2D, 2E and 2G in a recent publication (van Noort *et al.*, 2020). The other tested omega-1 glycoproteins ω 1 M5GN2 & Le^x and ω 1 single Le^x were immobilized at 3270.6 and 2604.8 RU, respectively. The ω 1 M5GN2 & Le^x protein carries a mixture of oligomannose-5 (**GL43** counterpart) and Le^x (**GL91** counterpart) *N*-glycans upon co-expression of d35S:sialFucT and d35S:sialGalT transferases, whereas the ω 1 single Le^x protein was expressed using a weaker, constitutive, Gpa2 promoter to reduce sialGalT expression, resulting in an almost complete lack of hybrid Le^x-type *N*-glycans and enabling the synthesis of relatively homogeneous *N*-glycans carrying a single Le^x motif (**GL91** counterpart). The MALDI-TOF glycosylation profiles are available from

1
2
3 respectively Figures 3A and 3C, in (Wilbers *et al.*, 2017). Engineered kappa-5 ($\kappa 5$) is
4 another glycoprotein from *S. mansoni* (Wilbers *et al.*, 2017) that displays high-
5 mannose *N*-glycans (M7GN2/M8GN2) larger than oligomannose-5 (Figure S5),
6 produced using kappa-5 (strain AGL) + P19 (strain AGL) with co-expression of the
7 SmFucTD and pHYG-GPAII-DrGalT transferases (van Noort *et al.*, 2020). Since no
8 Mannitou IgM binding could be detected to the engineered kappa-5, even upon an
9 immobilization rate of 3000 RU, this protein served as a blank. It was covalently
10 immobilized in the reference flow channel Fc1 in order to block the sensor surface
11 from α -specific binding and prepare Fc2-Fc1, Fc3-Fc1 and Fc4-Fc1 difference
12 sensorgrams. The binding was studied using increasing concentrations of Mannitou
13 IgM (59.375 nM, 118.75 nM, 237.5 nM, 475 nM, 950 nM) in 200 mM NaHCO₃, 500
14 mM NaCl, pH=7.8 buffer, at a flow rate of 30 μ l/min at 10°C. Each sample injection (3
15 min. association) was followed by 4 min. dissociation. All SPR data analysis was
16 performed with BIA Evaluation Software.

30 ***Mannitou Fab expression and purification***

31
32 cDNA fragments encoding the light chain (LC), and the heavy-chain variable
33 domain (VH) with the first domain of the heavy-chain constant region, referred to as
34 HC, were codon-optimized, synthesized and subcloned into a pUC57 *E. coli*
35 expression vector (GenScript). The DNA of interest was amplified by PCR using
36 primers HC_FP: GACTAGTACCGGTGAGGTGAAGCTTCTCGAGTCTGG, HC_RP:
37 GACTAGTGGTACCTTAGTGATGGTGATGG, LC_FP:
38 GACTAGTACCGGTGATGTTGTGGTGAAGTCAAACTCCACTC and LC_RP:
39 GACTAGTGGTACCTTAACACTCTTTCCTGTTG (FP is forward primer and RP is
40 reverse primer). The PCR products were digested with AgeI and KpnI restriction
41 enzymes, purified, and ligated into pHL-sec expression vectors. The HC insert was
42 cloned between a secretion signal sequence and in frame with a C-terminal 6-histidine
43 tag, whereas the LC fragment carried a stop codon before the KpnI cleavage site
44 (Aricescu *et al.*, 2006). The expression of Mannitou Fab was achieved by transient
45 transfection of adherent human embryonic kidney (HEK293T) cells, cultured in high-
46 glucose DMEM (Dulbecco's Modified Eagle's Medium) supplemented with L-
47 glutamine, non-essential amino acids and 2% FBS (Thermo Fisher Scientific). Equal
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 amounts of plasmid DNA encoding the heavy and light chains were used for
4 transfection - 1 μg of each vector per 1 ml of transfection volume. The DNA-PEI MAX
5 (Transfection Grade Linear Polyethylenimine Hydrochloride, MW = 40,000 Da)
6 solution (1:2) was incubated for 10 min at RT to allow the complex formation prior
7 transfection. The cells were grown in expanded-surface polystyrene roller bottles
8 (2125 cm^2 , CELLMASTER, Greiner Bio-One) at 37 °C, in a humidified atmosphere of
9 5% CO_2 in air, inside a roller bottle incubator. The cell-culture supernatant was
10 harvested 7 days post-transfection, clarified by centrifugation at 6 000 x g for 20 min,
11 then filtered through a 0.45 μm membrane and diluted threefold with PBS. The Fab
12 was by affinity chromatography using Ni-Sepharose 6 Fast Flow resin (Cytiva)
13 exploiting the selective His₆-tag at the C-terminus of the Fab HC. The binding buffer
14 consisted of 50 mM NaH_2PO_4 at pH=8.0 and 300 mM NaCl. Two consecutive washes
15 with ascending concentrations of imidazole (10 mM and 30 mM, pH=7.0) were
16 performed to eliminate as many impurities as possible. Mannitou Fab was eluted with
17 250 mM imidazole in a buffer of 50 mM NaH_2PO_4 at pH=7.0 and 300 mM NaCl. The
18 antibody was further purified by size-exclusion chromatography on a Superose 6
19 Increase 10/300 GL column (Cytiva) using buffer consisting of 20 mM 4-(2-
20 hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH=7.4 and 150 mM NaCl.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 37 ***Epitope mapping in STD-NMR Spectroscopy***

38
39 ^1H -STD NMR experiments were performed at 25°C on a Bruker AVANCE III
40 800 MHz spectrometer equipped with a cryoprobe. Samples were prepared in PBS
41 buffer in D_2O (pD=7.4) in 3 mm NMR tubes. The measurements were taken using a
42 40:1 molar ratio with a 1 mM concentration of the oligosaccharide epitope and a 25
43 μM concentration of Mannitou Fab. Chemical shifts for the epitope were recorded at
44 one off-resonance (no signals of protein or ligand) irradiation frequency set at 100 ppm
45 and two on-resonance irradiation frequencies, one set on the aliphatic region of the
46 protein signals (0.8 ppm) and one set on the aromatic region of the protein signals
47 (6.9 ppm). Protein saturation was achieved with a train of Gaussian-shaped pulses of
48 50 ms duration, with a total irradiation time of 2 s. STD spectra were obtained by
49 subtracting the on-resonance from the off-resonance (reference) spectrum.
50 Subtraction of ^1H -STD NMR spectra of the free ligands at 1 mm in D_2O was also
51
52
53
54
55
56
57
58
59
60

1
2
3 acquired to ensure that no direct irradiation of the oligosaccharide was taking place.
4
5 Finally, because some signals were present in STD spectra from the antibody, that
6
7 interfere in the analysis of the epitope protons, a second STD experiment was
8
9 acquired on a sample of the protein alone. This spectrum serves as a blank that can
10
11 be subtracted from the STDD spectra in the presence of the oligosaccharide epitope
12
13 to obtain the final, cleaner STDDD spectra. Data acquisition and processing were
14
15 performed with TopSpin 3.0 software (Bruker) and the figures were built using
16
17 MestReNova v.8.0.2.
18

19 ***Homology modelling and molecular docking***

21 A model of Mannitou Fab was obtained using homology modelling by supplying
22
23 the crystal structures of the heavy chain of human monoclonal antibody CR4354 (1.4
24
25 Å, PDB ID: 3N9G, sequence identity: 31%) and the light chain of IGG1-K B13I2 (2.8
26
27 Å, PDB ID: 1IGF, sequence identity: 79% to the program Modeller (Sali and Blundell,
28
29 1993). Subsequently, energy minimization of the global model was done applying
30
31 AMBER forcefield in order to remove putative steric clashes between the side chains.
32
33 Simulation of possible binding modes of the studied paucimannosidic *N*-glycans to
34
35 this three-dimensional model of Mannitou Fab was performed using GOLD docking
36
37 program (Jones *et al.*, 1997). GOLD is based on a genetic algorithm and, in this case,
38
39 considers the ligands as highly flexible as they are glycosidic compounds, while the
40
41 side chains of most of the residues are kept rigid. For the search procedure, a sphere
42
43 of 10 Å was centered on the CDRs of the variable region of the Fab. The different
44
45 binding poses were scored with the ChemPLP scoring function and the pose with the
46
47 best ChemPLP docking score was presented on the molecular surface of the
48
49 Mannitou Fab homology model for further structural analysis.
50

51 **Acknowledgements**

52
53
54 *This work was performed with financial support from the European commission,*
55
56 *H2020-MSCA-ITN grant 675671 to J. Bouckaert and J. Jiménez-Barbero, the Centre*
57
58 *National de la Recherche Scientifique (CNRS) and the Ministère de l'Enseignement*
59
60 *Supérieur et de la Recherche in France. We are grateful to our colleagues involved in*

1
2
3 the European Training Network GlycoVax, for communications and training to early-
4 stage researcher S. Robakiewicz. C. Bridot was supported by the National Agency for
5 Research (ANR project HICARE 17CE07-028-01), S. Semwal by 847568 – PEARL –
6 H2020-MSCA-COFUND-2018 granted to the foundation I-Site ULNE. N.G.A. Abrescia
7 was supported by grant RTI2018-095700-B-I00 from the Spanish Ministerio de
8 Ciencia, Innovacion y Universidades. MICINN is also thanked for the Severo Ochoa
9 Excellence Accreditation to the CIC bioGUNE (SEV-2016-0644). S. N. Savvides is
10 supported in part by grants from the FWO to K.V. (1524918N), a Concerted Research
11 Action grant from Ghent University to S.N.S. (BOF17-GOA-028), a Hercules
12 Foundation infrastructure grant (AUGE-11-029), and a programme grant from the VIB.
13 We are grateful to Cornelis H. Hokke and Linh Nguyen from Leiden University Medical
14 Center, The Netherlands, for N-glycan structural analysis of kappa-5. We would like
15 to give special thanks to Brigitte Schmidt, Simone Diestel and Birgit Zipser for sharing
16 the hybridoma cell line Laz6-189.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 References

- 32
33
34 Aebi M, Bernasconi R, Clerc S, Molinari M. 2010. N-glycan structures: recognition and
35 processing in the ER. *Trends Biochem.Sci.* 35, 74-82.
36 Arda A, Jimenez-Barbero J. 2018. The recognition of glycans by protein receptors.
37 Insights from NMR spectroscopy. *Chem Commun (Camb)* 54, 4761-4769.
38 Aricescu AR, Lu W, Jones EY. 2006. A time- and cost-efficient system for high-level
39 protein production in mammalian cells. *Acta Crystallogr., Sect.D:
40 Biol.Crystallogr.* 62, 1243-1250.
41 Bajt ML, Schmitz B, Schachner M, Zipser B. 1990. Carbohydrate epitopes involved in
42 neural cell recognition are conserved between vertebrates and leech. *J
43 Neurosci Res* 27, 276-285.
44 Becker Y, Forster S, Gielen GH, Loke I, Thaysen-Andersen M, Laurini C, Wehrand K,
45 Pietsch T, Diestel S. 2019. Paucimannosidic glycoepitopes inhibit tumorigenic
46 processes in glioblastoma multiforme. *Oncotarget* 10, 4449-4465.
47 Blaum BS, Neu U, Peters T, Stehle T. 2018. Spin ballet for sweet encounters:
48 saturation-transfer difference NMR and X-ray crystallography complement
49 each other in the elucidation of protein-glycan interactions. *Acta Crystallogr F
50 Struct Biol Commun* 74, 451-462.
51 Bouckaert J, Mackenzie J, de Paz JL, Chipwaza B, Choudhury D, Zavialov A,
52 Mannerstedt K, Anderson J, Pierard D, Wyns L *et al.* 2006. The affinity of the
53 FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia
54 coli pathotypes. *Molecular Microbiology* 61, 1556-1568.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Bruxelle JF, Kirilenko T, Qureshi Q, Lu N, Trattnig N, Kosma P, Pantophlet R. 2020. Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies. *Sci Rep* 10, 7582.
- Brzezicka K, Echeverria B, Serna S, van Diepen A, Hokke CH, Reichardt NC. 2015. Synthesis and microarray-assisted binding studies of core xylose and fucose containing N-glycans. *ACS Chem Biol* 10, 1290-1302.
- Campbell EJ, Owen CA. 2007. The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. *J Biol Chem* 282, 14645-14654.
- Chatterjee S, Lee LY, Kawahara R, Abrahams JL, Adamczyk B, Anugraham M, Ashwood C, Sumer-Bayraktar Z, Briggs MT, Chik JHL *et al.* 2019. Protein Paucimannosylation is an Enriched N-glycosylation Signature of Human Cancers. *Proteomics* 10.1002/pmic.201900010, e1900010.
- Dahmen AC, Fergen MT, Laurini C, Schmitz B, Loke I, Thaysen-Andersen M, Diestel S. 2015. Paucimannosidic glycoepitopes are functionally involved in proliferation of neural progenitor cells in the subventricular zone. *Glycobiology* 25, 869-880.
- de Vroome SW, Holst S, Gironde MR, van der Burgt YEM, Mesker WE, Tollenaar R, Wuhrer M. 2018. Serum N-glycome alterations in colorectal cancer associate with survival. *Oncotarget* 9, 30610-30623.
- Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M *et al.* 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. *Proceedings of the National Academy of Sciences of the United States of America* 108, 12669-12674.
- Flaster MS, Schley C, Zipser B. 1983. Generating monoclonal antibodies against excised gel bands to correlate immunocytochemical and biochemical data. *Brain Res* 277, 196-199.
- Gupta R, Brunak S. 2002. Prediction of glycosylation across the human proteome and the correlation to protein function. *Pac Symp Biocomput*, 310-322.
- Hajjar E, Mihajlovic M, Witko-Sarsat V, Lazaridis T, Reuter N. 2008. Computational prediction of the binding site of proteinase 3 to the plasma membrane. *Proteins* 71, 1655-1669.
- Henriques P, Dello Iacono L, Gimeno A, Biolchi A, Romano MR, Arda A, Bernardes GJL, Jimenez-Barbero J, Berti F, Rappuoli R *et al.* 2020. Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide. *Proceedings of the National Academy of Sciences of the United States of America* 117, 29795-29802.
- Houdou M, Foulquier F. 2020. [Panorama on congenital disorders of glycosylation (CDG): from 1980 to 2020]. *Med Sci (Paris)* 36, 735-746.
- Jones G, Willett P, Glen RC, Leach AR, Taylor R. 1997. Development and validation of a genetic algorithm for flexible docking. *J Mol Biol* 267, 727-748.
- Kozutsumi Y, Nakao Y, Teramura T, Kawasaki T, Yamashina I, Mutsaers JH, van Halbeek H, Vliegthart JF. 1986. Structures of oligomannoside chains of alpha-mannosidase from porcine kidney. *J Biochem* 99, 1253-1265.

- 1
2
3 Kunik V, Ashkenazi S, Ofran Y. 2012. Paratome: an online tool for systematic
4 identification of antigen-binding regions in antibodies based on sequence or
5 structure. *Nucleic Acids Res* 40, W521-524.
6
7 Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis
8 JW. 2007. Complex N-glycan number and degree of branching cooperate to
9 regulate cell proliferation and differentiation. *Cell* 129, 123-134.
10
11 Lau KS, Dennis JW. 2008. N-Glycans in cancer progression. *Glycobiology* 18, 750-
12 760.
13
14 Lauc G, Rudan I, Campbell H, Rudd PM. 2010. Complex genetic regulation of protein
15 glycosylation. *Mol. Biosyst.* 6, 329-335.
16
17 Liang P-H, Wang S-K, Wong C-H. 2007. Quantification of carbohydrate-protein
18 interactions using glycan microarrays: determination of surface and solution
19 dissociation constants. *J Am Chem Soc* 129, 11177-11184.
20
21 Lin AI, Philipsberg GA, Haltiwanger RS. 1994. Core fucosylation of high-mannose-
22 type oligosaccharides in GlcNAc transferase I-deficient (Lec1) CHO cells.
23 *Glycobiology* 4, 895-901.
24
25 Loke I, Kolarich D, Packer NH, Thaysen-Andersen M. 2016. Emerging roles of protein
26 mannosylation in inflammation and infection. *Mol Aspects Med* 51, 31-55.
27
28 Loke I, Ostergaard O, Heegaard NHH, Packer NH, Thaysen-Andersen M. 2017.
29 Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human
30 Neutrophil Elastase Modulates Its Immune Functions. *Mol Cell Proteomics* 16,
31 1507-1527.
32
33 Magorivska I, Donczo B, Dumych T, Karmash A, Boichuk M, Hychka K, Mihalj M,
34 Szabo M, Csanky E, Rech J *et al.* 2018. Glycosylation of random IgG
35 distinguishes seropositive and seronegative rheumatoid arthritis. *Autoimmunity*
36 51, 111-117.
37
38 Nkurunungi G, van Diepen A, Nassuuna J, Sanya RE, Nampijja M, Nambuya I,
39 Kabagenyi J, Serna S, Reichardt NC, van Ree R *et al.* 2019. Microarray
40 assessment of N-glycan-specific IgE and IgG profiles associated with
41 *Schistosoma mansoni* infection in rural and urban Uganda. *Sci Rep* 9, 3522.
42
43 Reily C, Stewart TJ, Renfrow MB, Novak J. 2019. Glycosylation in health and disease.
44 *Nat Rev Nephrol* 15, 346-366.
45
46 Sakae Y, Satoh T, Yagi H, Yanaka S, Yamaguchi T, Isoda Y, Iida S, Okamoto Y, Kato
47 K. 2017. Conformational effects of N-glycan core fucosylation of
48 immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa. *Sci*
49 *Rep* 7, 13780.
50
51 Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial
52 restraints. *J Mol Biol* 234, 779-815.
53
54 Schachter H. 2009. Paucimannose N-glycans in *Caenorhabditis elegans* and
55 *Drosophila melanogaster*. *Carbohydr Res* 344, 1391-1396.
56
57 Serna S, Etxebarria J, Ruiz N, Martin-Lomas M, Reichardt NC. 2010. Construction of
58 N-glycan microarrays by using modular synthesis and on-chip nanoscale
59 enzymatic glycosylation. *Chemistry* 16, 13163-13175.
60
61 Serna S, Yan S, Martin-Lomas M, Wilson IB, Reichardt NC. 2011. Fucosyltransferases
62 as synthetic tools: glycan array based substrate selection and core fucosylation
63 of synthetic N-glycans. *J Am Chem Soc* 133, 16495-16502.

- 1
2
3 Serna S, Hokke CH, Weissenborn M, Flitsch S, Martin-Lomas M, Reichardt NC. 2013.
4 Profiling glycosyltransferase activities by tritium imaging of glycan microarrays.
5 *Chembiochem* 14, 862-869.
6
7 Simon F, Bork K, Gnanapragassam VS, Baldensperger T, Glomb MA, Di Sanzo S, Ori
8 A, Horstkorte R. 2019. Increased Expression of Immature Mannose-Containing
9 Glycoproteins and Sialic Acid in Aged Mouse Brains. *Int J Mol Sci* 20
10
11 Stambuk T, Klasic M, Zoldos V, Lauc G. 2020. N-glycans as functional effectors of
12 genetic and epigenetic disease risk. *Mol Aspects Med*
13 10.1016/j.mam.2020.100891, 100891.
14
15 Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager
16 KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L *et al.* 2013.
17 Precision mapping of the human O-GalNAc glycoproteome through SimpleCell
18 technology. *EMBO J* 32, 1478-1488.
19
20 Szabo E, Hornung A, Monostori E, Bocskai M, Czibula A, Kovacs L. 2019. Altered Cell
21 Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus
22 Erythematosus. *Int J Mol Sci* 20
23
24 Taganna J, de Boer AR, Wuhrer M, Bouckaert J. 2011. Glycosylation changes as
25 important factors for the susceptibility to urinary tract infection.
26 *Biochem.Soc.Trans.* 39, 349-354.
27
28 Thaysen-Andersen M, Venkatakrishnan V, Loke I, Laurini C, Diestel S, Parker BL,
29 Packer NH. 2015. Human neutrophils secrete bioactive paucimannosidic
30 proteins from azurophilic granules into pathogen-infected sputum. *J Biol Chem*
31 290, 8789-8802.
32
33 Tjondro HC, Loke I, Chatterjee S, Thaysen-Andersen M. 2019. Human protein
34 paucimannosylation: cues from the eukaryotic kingdoms. *Biol Rev Camb Philos*
35 *Soc* 94, 2068-2100.
36
37 van Noort K, Nguyen DL, Kriechbaumer V, Hawes C, Hokke CH, Schots A, Wilbers
38 RHP. 2020. Functional characterization of *Schistosoma mansoni*
39 fucosyltransferases in *Nicotiana benthamiana* plants. *Sci Rep* 10, 18528.
40
41 Venkatakrishnan V, Thaysen-Andersen M, Chen SC, Nevalainen H, Packer NH. 2015.
42 Cystic fibrosis and bacterial colonization define the sputum N-glycosylation
43 phenotype. *Glycobiology* 25, 88-100.
44
45 Wilbers RH, Westerhof LB, van Noort K, Obieglo K, Driessen NN, Everts B, Gringhuis
46 SI, Schramm G, Goverse A, Smant G *et al.* 2017. Production and glyco-
47 engineering of immunomodulatory helminth glycoproteins in plants. *Sci Rep* 7,
48 45910.
49
50 Zipser B, Bello-DeOcampo D, Diestel S, Tai M-H, Schmitz B. 2012. Mannitou
51 monoclonal antibody uniquely recognizes paucimannose, a marker for human
52 cancer, stemness, and inflammation. *J Carbohydr Chem* 31, 504-518.
53
54
55
56
57
58
59
60